dupilumab – Medxy AI

High Adherence to Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Insights from Real-World US Data

By MedXY 08/21/2025

Real-world analysis of 3318 US patients with CRSwNP treated with dupilumab demonstrated high persistence and adherence at 12 months, with significant rates of treatment reinitiation after discontinuation, underscoring dupilumab's sustained use in clinical practice.

Clinical Updates

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

By MedXY 08/02/2025

Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.

Clinical Updates Wellness & Lifestyle

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

By MedXY 07/31/2025

Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.